<?xml version='1.0' encoding='utf-8'?>
<document id="30068519"><sentence text="Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions."><entity charOffset="47-59" id="DDI-PubMed.30068519.s1.e0" text="Itraconazole" /></sentence><sentence text="Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a bottom-up approach is challenging, not only due to complex saturable pharmacokinetics (PK) and the presence of three metabolites exhibiting CYP3A4 inhibition, but also because of discrepancies in reported in vitro data"><entity charOffset="58-70" id="DDI-PubMed.30068519.s2.e0" text="itraconazole" /></sentence><sentence text=" The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole in order to increase the confidence in its drug-drug interaction (DDI) predictions"><entity charOffset="94-106" id="DDI-PubMed.30068519.s3.e0" text="itraconazole" /></sentence><sentence text=" To achieve this, key in vitro and in vivo data for itraconazole and its major metabolites were generated"><entity charOffset="52-64" id="DDI-PubMed.30068519.s4.e0" text="itraconazole" /></sentence><sentence text=" These data were crucial to developing a novel bottom-up PBPK model in Simcyp (Simcyp Ltd" /><sentence text=", Certara, Sheffield, United Kingdom) for itraconazole and two of its major metabolites: hydroxy-itraconazole (OH-ITZ) and keto-itraconazole (keto-ITZ)"><entity charOffset="42-54" id="DDI-PubMed.30068519.s6.e0" text="itraconazole" /><entity charOffset="89-109" id="DDI-PubMed.30068519.s6.e1" text="hydroxy-itraconazole" /><entity charOffset="111-117" id="DDI-PubMed.30068519.s6.e2" text="OH-ITZ" /><entity charOffset="123-140" id="DDI-PubMed.30068519.s6.e3" text="keto-itraconazole" /><entity charOffset="142-150" id="DDI-PubMed.30068519.s6.e4" text="keto-ITZ" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e0" e2="DDI-PubMed.30068519.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e0" e2="DDI-PubMed.30068519.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e0" e2="DDI-PubMed.30068519.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e0" e2="DDI-PubMed.30068519.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e0" e2="DDI-PubMed.30068519.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e1" e2="DDI-PubMed.30068519.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e1" e2="DDI-PubMed.30068519.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e1" e2="DDI-PubMed.30068519.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e1" e2="DDI-PubMed.30068519.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e2" e2="DDI-PubMed.30068519.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e2" e2="DDI-PubMed.30068519.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e2" e2="DDI-PubMed.30068519.s6.e4" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e3" e2="DDI-PubMed.30068519.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30068519.s6.e3" e2="DDI-PubMed.30068519.s6.e4" /></sentence><sentence text=" Performance of the model was validated using prespecified acceptance criteria against different dosing regimens, formulations for 29 PK, and DDI studies with midazolam and other CYP3A4 substrates" /><sentence text=" The main outcome is an accurate PBPK model that simultaneously predicts the PK profiles of itraconazole, OH-ITZ, and keto-ITZ"><entity charOffset="92-104" id="DDI-PubMed.30068519.s8.e0" text="itraconazole" /><entity charOffset="106-112" id="DDI-PubMed.30068519.s8.e1" text="OH-ITZ" /><pair ddi="false" e1="DDI-PubMed.30068519.s8.e0" e2="DDI-PubMed.30068519.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30068519.s8.e0" e2="DDI-PubMed.30068519.s8.e1" /></sentence><sentence text=" In addition, itraconazole DDIs with midazolam and other CYP3A4 substrates were successfully predicted within a 2-fold error"><entity charOffset="14-26" id="DDI-PubMed.30068519.s9.e0" text="itraconazole" /><entity charOffset="37-46" id="DDI-PubMed.30068519.s9.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.30068519.s9.e0" e2="DDI-PubMed.30068519.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30068519.s9.e0" e2="DDI-PubMed.30068519.s9.e1" /></sentence><sentence text=" Prediction precision and bias of DDI expressed as geometric mean fold error were for the area under the concentration-time curve and peak concentration, 1" /><sentence text="06 and 0" /><sentence text="96, respectively" /><sentence text=" To conclude, in this paper a comprehensive data set for itraconazole and its metabolites is provided that enables bottom-up mechanism-based PBPK modeling"><entity charOffset="57-69" id="DDI-PubMed.30068519.s13.e0" text="itraconazole" /></sentence><sentence text=" The presented model is applicable for studying the contribution from the metabolites and allows improved assessments of itraconazole DDI"><entity charOffset="121-137" id="DDI-PubMed.30068519.s14.e0" text="itraconazole DDI" /></sentence><sentence text="" /></document>